It is clear from the 4C that the high cash burn for the quarter...

It is clear from the 4C that the high cash burn for the quarter was associated with clinical trial start-up costs - setting up the sites. This is significantly more expensive than ongoing recruitment and running the trial. We will not see anywhere near those costs on an ongoing basis. I don't expect we will see another cap raise for FSGS.
Also great to see they have 15% recruited. At that rate I would be hoping to see full recruitment by Christmas (would be a good present) meaning first data by mid next year? The cash should definitely get us to there. Certainly if we were close I imagine they would consider another loan from Mr Meurs or something similar. Wouldn't make sense to raise based on the option structure in place.
It also seems like Nina and Ash have been very visible lately - hopefully something comes out of that.